V
Valeriy Breder
Researcher at University of Texas MD Anderson Cancer Center
Publications - 53
Citations - 8152
Valeriy Breder is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Sorafenib & Hepatocellular carcinoma. The author has an hindex of 11, co-authored 46 publications receiving 3814 citations. Previous affiliations of Valeriy Breder include Russian Academy.
Papers
More filters
Journal ArticleDOI
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed O Kaseb,Daneng Li,Wendy Verret,Derek-Zhen Xu,Sairy Hernandez,Juan Liu,Chen Huang,Sohail M. Mulla,Yulei Wang,Ho Yeong Lim,Andrew X. Zhu,Ann-Lii Cheng,IMbrave Investigators +21 more
TL;DR: In patients with unresectable hepatocellular carcinoma, atezolIZumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib.
Journal ArticleDOI
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
Journal ArticleDOI
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn,Baek-Yeol Ryoo,Philippe Merle,Masatoshi Kudo,Mohamed Bouattour,Ho Yeong Lim,Valeriy Breder,Julien Edeline,Yee Chao,Sadahisa Ogasawara,Thomas Yau,Marcelo Garrido,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Scot Ebbinghaus,Erluo Chen,Abby B. Siegel,Andrew X. Zhu,Ann-Lii Cheng +19 more
TL;DR: The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population, and one-sided significance thresholds for OS and PFS did not reach statistical significance per specified criteria.
Journal ArticleDOI
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Ho Yeong Lim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed Kaseb,Daneng Li,Wendy Verret,Hui Shao,Juan Liu,Lindong Li,Andrew X. Zhu,Ann-Lii Cheng +17 more
TL;DR: Atezo + bev has been approved globally for pts with unresectable HCC who have not received prior systemic therapy, based on results from IMbrave150 (NCT03434379).
Journal ArticleDOI
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Ghassan K. Abou-Alfa,Stephen Chan,Masatoshi Kudo,George K. K. Lau,Robin Kate Kelley,Junji Furuse,Wattana Sukeepaisarnjaroen,Yoon-Koo Kang,Tuoc Dao,Enrico N. De Toni,Lorenza Rimassa,Valeriy Breder,Alexander Vasilyev,Alexandra Heurgué,Vincent C. Tam,Kabir Mody,Satheesh Chiradoni Thungappa,Philip He,Alejandra Negro,Bruno Sangro +19 more
TL;DR: The combination of a single priming dose of T plus D in STRIDE displayed superior efficacy and a favorable benefit-risk profile vs S and was the first large phase 3 trial with a diverse, representative uHCC population and extensive long-term follow-up to assess both mono- and combination immunotherapy.